R Squared’s Celldex Therapeutics CLDX Stock Holding History

R Squared’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-880	Closed	-$22.2K	–	536
2024 Q4	$22.2K	Buy	+880	New	+$23.9K	0.02%	828

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

R Squared's CLDX Position: Q1 2025 in Review

R Squared sold out of Celldex Therapeutics (CLDX) in Q1 2025, closing a stake of 880 shares — an estimated $22.2K sold.

R Squared first reported a position in CLDX in Q4 2024 and held it in 1 quarter. The position peaked at $22.2K in Q4 2024. 171 funds tracked by Wall St. Rank hold CLDX as of Q1 2025.

R Squared reported no remaining Celldex Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 880 Celldex Therapeutics shares in Q1 2025, an estimated $22.2K.
R Squared first reported a position in Celldex Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Celldex Therapeutics position peaked at $22.2K in Q4 2024.
171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.